InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Age-related Macular Degeneration (AMD) Drugs Market Size, Share & Trends Analysis Report By Products (Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre, Other Products), Molecules (Ranibizumab, Aflibercept, Faricimab, Pegcetoplan, Other Molecules), Type of AMD (Wet AMD, Dry AMD), Approval type (Biologic, Biosimilar) End User (Hospitals, Specialty Centers, Long-Term Care Facilities)- Market Outlook And Industry Analysis 2031″
The Global Age-related Macular Degeneration (AMD) Drugs Market is valued at US$ 9.58 Bn in 2023, and it is expected to reach US$ 19.77 Bn by 2031, with a CAGR of 9.7% during the forecast period of 2024-2031.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2854
Age-related Macular Degeneration (AMD) is a progressively impairing ocular disorder that predominantly affects the elderly, resulting from the degeneration of the macula—the central portion of the retina responsible for high-resolution, detailed vision. AMD is generally categorized into two main types: dry AMD, the more common form characterized by a gradual deterioration in vision, and wet AMD, which involves rapid vision loss due to the growth of abnormal blood vessels beneath the retina.
The current AMD therapeutics market is largely driven by anti-vascular endothelial growth factor (anti-VEGF) treatments, such as Eylea and Lucentis, which are primarily indicated for wet AMD. These agents function by inhibiting neovascularization, thereby mitigating further vision deterioration. In recent developments, innovative therapies like Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) have emerged, addressing the long-standing treatment gap in dry AMD, particularly for patients with geographic atrophy.
The clinical and commercial value of AMD therapies lies in their capacity to delay disease progression and sustain visual acuity. Market expansion is being propelled by demographic shifts such as an aging population, a rising incidence of AMD linked to environmental and lifestyle factors, and ongoing advancements in ophthalmologic science.
The introduction of new therapies for dry AMD marks a critical milestone in treatment innovation, offering improved patient outcomes and quality of life. Collectively, these trends highlight the growing potential of the AMD treatment market to respond to evolving clinical demands and population health needs.
List of Prominent Players in the Age-related Macular Degeneration (AMD) Drugs Market:
- Regeneron Pharmaceuticals Inc. (US)
- Bayer AG (Germany)
- F. Hoffmann-La Roche AG (Switzerland)
- Novartis AG (Switzerland)
- Apellis Pharmaceuticals, Inc. (US)
- Coherus BioSciences, Inc. (US)
- Astellas Pharma Inc. (Japan)
- Biogen (US)
- STADA Arzneimittel AG (Germany)
- Formycon AG (Germany)
- Biocon. (India)
- Outlook Therapeutics, Inc. (US)
- Intas Pharmaceuticals Ltd. (India)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Chengdu Kanghong Biotech Company (China)
- Sandoz Group AG (Switzerland)
- Stealth BioTherapeutics Inc. (US)
- Ocular Therapeutix, Inc. (US)
- Opthea Limited, Inc. (Australia)
- Kodiak Sciences Inc. (US)
- Innovent Biologics, Inc. (China)
- Bio-Thera Solution Inc. (China)
- Alvotech (Iceland)
- Alteogen Inc. (South Korea)
- Shanghai Henlius Biotech, Inc. (China)
- Amgen Inc. (US)
- Ocumension Therapeutics. (China)
- Adverum Biotechnologies, Inc. (US)
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02
Market Dynamics
Drivers:
The Age-related Macular Degeneration (AMD) drugs market is witnessing sustained growth, driven by multiple key factors. The increasing global prevalence of AMD, particularly among the elderly, is closely linked to lifestyle-related risk factors such as unhealthy diets, tobacco use, and lack of physical activity.
Innovations in drug development, including the launch of novel therapies like Pegcetacoplan (Syfovre) and Avacincaptad Pegol (IZERVAY) for dry AMD, along with longer-acting anti-VEGF agents for wet AMD, have broadened treatment options and improved clinical outcomes. Improved reimbursement policies have also enhanced treatment accessibility and adherence.
Furthermore, emerging economies in Asia-Pacific and Latin America present significant growth opportunities, supported by rising investments in research and development. The shift toward personalized medicine and the increasing number of collaborations between public and private sectors are further advancing therapeutic innovation and enabling more tailored treatment approaches, ultimately contributing to improved patient satisfaction and sustained market expansion.
Challenges:
Despite positive momentum, the AMD drugs market continues to face notable challenges. The high cost of branded anti-VEGF therapies, such as Eylea and Vabysmo, often limits patient access and adherence, leading some to seek off-label alternatives for economic reasons. In addition, the treatment landscape for dry AMD remains relatively limited, with few approved pharmacologic options and continued dependence on nutritional supplements, thereby constraining overall market growth.
Regional Trends:
North America currently leads the global AMD drugs market, supported by a robust pharmaceutical research environment and the presence of major industry stakeholders and research institutions. The region benefits from strong investment in research and development, facilitating the introduction and approval of innovative treatments, including biosimilars such as Enzeevu for wet AMD.
An advanced healthcare infrastructure allows for early diagnosis and effective disease management, while a favorable regulatory climate—exemplified by the U.S. FDA’s expedited review and approval processes—continues to promote market innovation. Comprehensive reimbursement systems and active engagement between public and private entities further enhance access to care, stimulate product development, and reinforce North America’s dominant position in the global AMD therapeutics market.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2854
Recent Developments:
- In August 2023, Regeneron Pharmaceuticals announced that the U.S. FDA has approved EYLEA HD (aflibercept) 8 mg for treating wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR).
- In March 2022, Novartis announced that the European Commission (EC) has approved Beovu® (brolucizumab) 6 mg for treating visual impairment due to diabetic macular edema (DME), marking its second EC-approved indication following wet age-related macular degeneration in 2020.
Segmentation of Age-related Macular Degeneration (AMD) Drugs Market-
By Products:
- Lucentis
- Eylea & Eylea HD
- Vabysmo
- Syfovre
- Other Products
By Molecules:
- Ranibizumab
- Aflibercept
- Faricimab
- Pegcetoplan
- Other Molecules
By Type of AMD:
- Wet AMD
- Dry AMD
By Approval type:
- Biologic
- Biosimilar
By End User:
- Hospitals
- Specialty Centers
- Long-Term Care Facilities
By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com
